Reviewed
Verified by SAC team
+20
XP on completion
Right Dose, Wrong Value
NaturesPlus

NaturesPlus Rhodiola Extended Release Review

NaturesPlus does two things right: 250 mg lands inside the 200-400 mg trial window, and it's standardized to the 3% rosavins / 1% salidroside ratio. Then it loses the plot on value — the bilayer 'extended release' delivery has no rhodiola-specific evidence it beats a standard cap, and 30 tablets at ~$17 makes cost-per-day among the worst here.

Check on Amazon

Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.

Read the complete Rhodiola Rosea guide →
▸ THE SCORE

How we built the SAC Product Score™6.5/10

Standardization & Actives Match30%7.5/10

Standardized to 3% rosavins / 1% salidroside — the correct studied ratio. Solid on the core axis, a notch below the specialist brands on documentation.

Third-Party Testing20%5.5/10

cGMP, hypoallergenic and vegetarian, but little in the way of published third-party testing or COA transparency relative to NOW or Thorne.

Dose vs Clinical Range25%7.5/10

250 mg per tablet is squarely within the 200-400 mg window — a genuine strength. The extended-release delivery, however, is not something the trials used or validated.

Tolerability & Safety10%7.5/10

250 mg is a moderate, well-tolerated dose. No specific safety concern beyond the usual advice to take rhodiola earlier in the day.

Value15%3.5/10

Only 30 tablets at ~$17 makes this among the most expensive per day on the list. The extended-release premium buys a benefit that isn't evidenced for rhodiola.

▸ SPECS

The product at a glance

Form
Bilayer extended-release tablet
Dose
250 mg extract/tablet
Count
30 tablets (~30-day supply)
Standardization
3% rosavins / 1% salidroside
Testing
cGMP, hypoallergenic, vegetarian
Cost per dose
~$0.57/tablet
▸ TRUTH CHECK

Marketing claims vs. reality

Not verified

Extended-release delivery improves rhodiola's effect

The classic fatigue trials used standard extract capsules, not extended-release tablets. There is no rhodiola-specific evidence that a timed-release format outperforms a normal cap (Darbinyan 2000, PMID 11081987).

Verified

250 mg is within the clinically studied dose range

250 mg falls inside the 200-400 mg range used across the SHR-5 fatigue trials, making the dose itself well-targeted (Olsson 2009, PMID 19016404).

▸ THE DEEP DIVE

What our test actually found

01Right dose, wrong economics

The 250 mg / correct-ratio core is exactly what you want — it's the same dose logic that puts Life Extension at #1. The problem is that NaturesPlus wraps it in a costlier delivery format and a 30-count bottle, so you pay far more per day for it.

02Extended release is a delivery claim, not a proven benefit

Timed-release can matter for some drugs, but rhodiola's trials never tested it. Absent that evidence, the format is a marketing differentiator, not a reason to pay a premium.

▸ THE TRADE-OFFS

Pros & cons, no sugar-coating

Pros
  • 250 mg dose lands squarely in the 200-400 mg trial window
  • Correct 3% rosavins / 1% salidroside standardization
  • cGMP, hypoallergenic, vegetarian formulation
  • Moderate dose is easy to tolerate and start with
Cons
  • Extended-release delivery has no rhodiola-specific evidence it helps
  • Only 30 tablets — among the worst cost-per-day on the list
▸ THE BOTTOM LINE

Fine dose, hard to justify the price

If the extended-release format appeals to you and cost isn't a factor, the 250 mg dose and correct ratio are legitimately good. For everyone else, Life Extension delivers the same 250 mg and ratio at roughly half the cost-per-day without the unproven delivery gimmick.

Check NaturesPlus on Amazon
▸ ALTERNATIVES

If this doesn’t fit — try these

▸ RESEARCH

Sources & further reading

  1. Darbinyan V, Kteyan A, Panossian A, et al. Rhodiola rosea in stress induced fatigue--a double blind cross-over study of a standardized extract SHR-5. Phytomedicine. 2000;7(5):365-371.Darbinyan V, Kteyan A, Panossian A, et al. · 2000 · Phytomedicine · PMID 11081987

    Rhodiola rosea in stress induced fatigue — a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty

    Standard (non-timed-release) SHR-5 capsules reduced stress fatigue, the format the evidence base actually rests on.

  2. Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75(2):105-112.Olsson EM, von Schéele B, Panossian AG · 2009 · Planta Medica · PMID 19016404

    A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue

    Effective doses fell in the low-hundreds of mg, confirming 250 mg as a well-targeted dose.